NCT03111238 - The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 5, 2017

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions

Peripheral Arterial Disease (PAD)Diabetes Mellitus (DM)Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Cardiovascular DiseaseCritical Limb Ischemia (CLI)

Interventions

DRUG

REX-001

REX-001 is administered through an intra-arterial catheter.

DRUG

Placebo

Placebo is administered through an intra-arterial catheter.

Trial Locations (15)

Unknown

Fakultní nemocnice Ostrava, Ostrava

Vitkovicka nemocnice a. s. Vaskularni centrum, Ostrava

Klinikum der Goethe-Universität Frankfurt, Frankfurt

Pécsi Tudományegyetem, PTE-KK I. sz Belgyógyászati Klinika, Pécs

Instytut Hematologii i Transfuzjologii, Warsaw

Centro Hospitalar de São João, Porto

Hospital Universitari Germans Trias i Pujol, Badalona

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Universitario Puerta del Mar, Cadiz

First site: Hospital Universitario Reina Sofía, Córdoba

Complejo Hospitalario Universitario de Granada, Hospital del Campus de la Salud, Granada

Hospital Universitario de la Princesa, Madrid

Hospital General Universitario Morales Meseguer, Murcia

Hospital Universitario Virgen de Valme, Seville